565 related articles for article (PubMed ID: 32821070)
1. Differential regulation of JAK/STAT-signaling in patients with ulcerative colitis and Crohn's disease.
Cordes F; Foell D; Ding JN; Varga G; Bettenworth D
World J Gastroenterol; 2020 Jul; 26(28):4055-4075. PubMed ID: 32821070
[TBL] [Abstract][Full Text] [Related]
2. Janus Kinase Inhibitors Differentially Inhibit Specific Cytokine Signals in the Mesenteric Lymph Node Cells of Inflammatory Bowel Disease Patients.
Hindmarch DC; Malashanka S; Shows DM; Clarke AS; Lord JD
J Crohns Colitis; 2024 Apr; 18(4):628-637. PubMed ID: 37855324
[TBL] [Abstract][Full Text] [Related]
3. Understanding the efficacy of individual Janus kinase inhibitors in the treatment of ulcerative colitis for future positioning in inflammatory bowel disease treatment.
Nakase H
Immunol Med; 2023 Sep; 46(3):121-130. PubMed ID: 37036140
[TBL] [Abstract][Full Text] [Related]
4. The evolving role of JAK inhibitors in the treatment of inflammatory bowel disease.
Gupta N; Papasotiriou S; Hanauer S
Expert Rev Clin Immunol; 2023; 19(9):1075-1089. PubMed ID: 37226522
[TBL] [Abstract][Full Text] [Related]
5. Small molecule drug discovery targeting the JAK-STAT pathway.
Lv Y; Mi P; Babon JJ; Fan G; Qi J; Cao L; Lang J; Zhang J; Wang F; Kobe B
Pharmacol Res; 2024 Jun; 204():107217. PubMed ID: 38777110
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of JAK inhibitors in Ulcerative Colitis.
Ferrante M; Sabino J
J Crohns Colitis; 2020 Aug; 14(Supplement_2):S737-S745. PubMed ID: 31879750
[TBL] [Abstract][Full Text] [Related]
7. Clinical and Mechanistic Characteristics of Current JAK Inhibitors in IBD.
Pippis EJ; Yacyshyn BR
Inflamm Bowel Dis; 2021 Oct; 27(10):1674-1683. PubMed ID: 33295611
[TBL] [Abstract][Full Text] [Related]
8. Kinase Signaling in Colitis-Associated Colon Cancer and Inflammatory Bowel Disease.
Temby M; Boye TL; Hoang J; Nielsen OH; Gubatan J
Biomolecules; 2023 Nov; 13(11):. PubMed ID: 38002302
[TBL] [Abstract][Full Text] [Related]
9. Upadacitinib in Crohn's disease.
Dignass A; Esters P; Flauaus C
Expert Opin Pharmacother; 2024 Mar; 25(4):359-370. PubMed ID: 38512115
[TBL] [Abstract][Full Text] [Related]
10. Prioritization in inflammatory bowel disease therapy.
Herrlinger KR; Stange EF
Expert Rev Gastroenterol Hepatol; 2023; 17(8):753-767. PubMed ID: 37480322
[TBL] [Abstract][Full Text] [Related]
11. The role of filgotinib in ulcerative colitis and Crohn's disease.
Fanizza J; D'Amico F; Lauri G; Martinez-Dominguez SJ; Allocca M; Furfaro F; Zilli A; Fiorino G; Parigi TL; Radice S; Peyrin-Biroulet L; Danese S
Immunotherapy; 2024 Feb; 16(2):59-74. PubMed ID: 38009327
[TBL] [Abstract][Full Text] [Related]
12. JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition.
Luo Y; Alexander M; Gadina M; O'Shea JJ; Meylan F; Schwartz DM
J Allergy Clin Immunol; 2021 Oct; 148(4):911-925. PubMed ID: 34625141
[TBL] [Abstract][Full Text] [Related]
13. Update for surgeons on novel induction treatments for acute severe inflammatory bowel disease associated colitis.
Levar T; Johnston M; Ding NS; Behrenbruch C
ANZ J Surg; 2024 May; 94(5):795-803. PubMed ID: 38450582
[TBL] [Abstract][Full Text] [Related]
14. Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions.
Ryguła I; Pikiewicz W; Kaminiów K
Molecules; 2023 Dec; 28(24):. PubMed ID: 38138551
[TBL] [Abstract][Full Text] [Related]
15. The Role of JAK/STAT Signaling Pathway and Its Downstream Influencing Factors in the Treatment of Atherosclerosis.
Zhang X; Chen S; Yin G; Liang P; Feng Y; Yu W; Meng D; Liu H; Zhang F
J Cardiovasc Pharmacol Ther; 2024; 29():10742484241248046. PubMed ID: 38656132
[TBL] [Abstract][Full Text] [Related]
16. JAK-STAT Pathway Inhibition and their Implications in COVID-19 Therapy.
Satarker S; Tom AA; Shaji RA; Alosious A; Luvis M; Nampoothiri M
Postgrad Med; 2021 Jun; 133(5):489-507. PubMed ID: 33245005
[TBL] [Abstract][Full Text] [Related]
17. The JAK-STAT Pathway as a Therapeutic Strategy in Cancer Patients with Immune Checkpoint Inhibitor-Induced Colitis: A Narrative Review.
Gravina AG; Pellegrino R; Esposito A; Cipullo M; Romeo M; Palladino G; Iodice P; Federico A; Troiani T
Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339367
[TBL] [Abstract][Full Text] [Related]
18. JAK-STAT inhibitors in Immune mediated diseases: An Overview.
Shah RJ; Banerjee S; Raychaudhuri S; Raychaudhuri SP
Indian J Dermatol Venereol Leprol; 2023; 89(5):691-699. PubMed ID: 37609730
[TBL] [Abstract][Full Text] [Related]
19. Upadacitinib: Mechanism of action, clinical, and translational science.
Mohamed MF; Bhatnagar S; Parmentier JM; Nakasato P; Wung P
Clin Transl Sci; 2024 Jan; 17(1):e13688. PubMed ID: 37984057
[TBL] [Abstract][Full Text] [Related]
20. Histological Outcomes And Jak-Stat Signalling In Ulcerative Colitis Patients Treated With Tofacitinib.
van Gennep S; Fung ICN; de Jong DC; Ramkisoen RK; Clasquin E; de Jong J; de Vries LCS; de Jonge WJ; Gecse KB; Löwenberg M; Woolcott JC; Mookhoek A; D'Haens GR
J Crohns Colitis; 2024 Mar; ():. PubMed ID: 38506097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
